Xspray Pharma
Xspray Pharma is a pharmaceutical company dedicated to developing improved versions of marketed protein kinase inhibitors (PKIs) for cancer treatment using its innovative, patented HyNap technology. The company's mission is to enhance drug properties, improve patient quality of life, and establish a strong market presence with its unique technology and market approach.
Industries
Nr. of Employees
small (1-50)
Xspray Pharma
Xspray Pharma AB Scheeles väg 2 171 65 Solna
Patents
Products
Lead product candidate: improved dasatinib oral formulation
An oral dasatinib formulation developed using an amorphous formulation platform to provide pH-independent absorption, reduced inter‑patient variability, and potential dose reduction while demonstrating bioequivalence to the reference product in clinical studies.
Lead product candidate: improved dasatinib oral formulation
An oral dasatinib formulation developed using an amorphous formulation platform to provide pH-independent absorption, reduced inter‑patient variability, and potential dose reduction while demonstrating bioequivalence to the reference product in clinical studies.
Services
Out-licensing and partnering for development and commercialization of improved formulations based on the company's amorphous formulation platform.
Design and execution of bioequivalence and pharmacokinetic studies to support regulatory submissions for improved oral formulations.
Coordination of commercial-scale GMP manufacturing and stability program execution through contract manufacturing organizations.
Out-licensing and partnering for development and commercialization of improved formulations based on the company's amorphous formulation platform.
Design and execution of bioequivalence and pharmacokinetic studies to support regulatory submissions for improved oral formulations.
Coordination of commercial-scale GMP manufacturing and stability program execution through contract manufacturing organizations.
Expertise Areas
- Formulation development for low-solubility oral drugs
- Platform-based lifecycle development for oncology drugs
- Clinical trial management for bioequivalence and PK studies
- Regulatory affairs for FDA submissions and orphan designation
Key Technologies
- Amorphous solid dispersion
- Particle engineering (nozzle-based spray technology)
- Oral tablet formulation
- Bioequivalence and pharmacokinetic testing